The alpha chemokine "Interferon gamma-induced protein 10" (IP-10) in Graves' disease;La chemochina alfa "Interferon gamma-induced protein 10" (IP-10) nel morbo di Graves

Clinica Terapeutica

Volumn 165, Issue 2, 2014, Pages

  Mancusi, C ^a   Di Domenicantonio, A ^a   Politti, U ^a   Giuggioli, D ^b   Antonelli, A ^a   Ferri, C ^b   Fallahi, P ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Autoimmunity; Graves' disease; Graves'ophthalmoapthy; IP 10; Thyroid eye disease

Indexed keywords

CXCL10 PROTEIN, HUMAN; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

AUTOIMMUNE DISEASES; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMAN; PHYSIOLOGY;

AUTOIMMUNE DISEASES; CHEMOKINE CXCL10; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS;

EID: 84899721348     PISSN: 00099074     EISSN: 19726007     Source Type: Journal    
DOI: 10.7471/CT.2014.1705     Document Type: Article

References (90)

1. Godessart N, Kunkel SL. Chemokines in autoimmune disease. Curr Opin Immunol 2001; 6:670-5
2. Kelsen SG, Aksoy MO, Yang Y, et al. The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2004; 287:L584-91
3. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197:1537-49
4. Bodnar RJ, Yates CC, Rodgers ME, et al. IP-10 induces dissociation of newly formed blood vessels. J Cell Sci 2009; 122:2064-77
5. Swaminathan GJ, Holloway DE, Colvin RA, et al. Crystal structures of oligomeric forms of the IP-10/CXCL10 chemokine. Structure 2003; 11:521-32
6. Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev 2009; 8:379-83
7. Taub DD, Lloyd AR, Conlon K, et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993; 177:1809-14
8. Schulthess FT, Paroni F, Sauter NS, et al. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab 2009; 9:125-39
9. Soejima K, Rollins BJ. A functional IFN-gamma-inducible protein-10/ CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan. J Immunol 2001; 167:6576-82
10. Campanella GS, Lee EM, Sun J, et al. CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10). J Biol Chem 2003; 278:17066-74
11. Campanella GS, Colvin RA, Luster AD. CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One 2010; 5:e12700
12. Antonelli A, Rotondi M, Fallahi P, et al. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine 2006; 34:32-8
13. Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2013 (in press)
14. Engel MA, Neurath MF. Anticancer properties of the IL-12 family--focus on colorectal cancer. Curr Med Chem 2010; 17:3303-8
15. Antonelli A, Ferri C, Ferrari SM, et al. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 2008; 8:18-23
16. Antonelli A, Ferrari SM, Frascerra S, et al. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine 2011; 55:288-93
17. Antonelli A, Fallahi P, Ferrari SM, et al. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med 2008; 25:1349-53
18. Pupilli C, Giannini S, Marchetti P, et al. Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets. Diabetes 1999; 48:2309-15
19. Antonelli A, Fallahi P, Nesti C, et al. Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp Immunol 2001; 126:426-31
20. Antonelli A, Tuomi T, Nannipieri M, et al. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002; 45:1298-306
21. Antonelli A, Baj G, Marchetti P, et al. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes 2001; 50:985-91
22. Cossu A, Ferrannini E, Fallahi P, et al. Antibodies recognizing specific Mycobacterium avium subsp. paratuberculosis's MAP3738c protein in type 1 diabetes mellitus children are associated with serum Th1 (CXCL10) chemokine. Cytokine 2013; 61:337-9
23. Lee EY, Lee ZH, Song YW. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun Rev 2013; 12:554-7
24. Lacotte S, Brun S, Muller S, et al. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009; 1173:310-7
25. Antonelli A, Ferri C, Fallahi P, et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study. Rheumatology (Oxford) 2008; 47:45-9
26. Antonelli A, Ferri C, Fallahi P, et al. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol 2008; 35:1809-11
27. Antonelli A, Delle Sedie A, Fallahi P, et al. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. J Rheumatol 2006; 33:2026-28
28. Antonelli A, Fallahi P, Delle Sedie A, et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol 2009; 27:22-7
29. Antonelli A, Fallahi P, Delle Sedie A, et al. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity 2008; 41:537-42
30. Su R, Nguyen ML, Agarwal MR, et al. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir Res 2013; 14:121
31. Antonelli A, Fazzi P, Fallahi P, et al. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest 2006; 130:526-32
32. Antonelli A, Ferri C, Fallahi P, et al. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM 2004; 97:499-506
33. Antonelli A, Ferri C, Fallahi P, et al. High Values of CXCL10 Serum Levels in Mixed Cryoglobulinemia Associated With Hepatitis C Infection. Am J Gastroenterol 2008; 103:2488-94
34. Ferri C, Antonelli A, Mascia MT, et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007; 39:S13-21
35. Ferri C, Antonelli A, Mascia MT, et al. B-cells and mixed cryoglobulinemia. Autoimmun Rev 2007; 7:114-20
36. Tozzoli R, Barzilai O, Ram M, et al. Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev 2008; 8:112-5
37. Burek CL, Rose NR. Autoimmune thyroiditis and ROS. Autoimmun Rev 2008; 7:530-7
38. Antonelli A, Rotondi M, Fallahi P, et al. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004; 89:5496-9
39. Antonelli A, Fallahi P, Rotondi M, et al. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006; 154:651-8
40. Kimura H, Kimura M, Rose NR, et al. Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto's thyroiditis. Exp Mol Pathol 2004; 77:161-7
41. Fiore E, Rago T, Latrofa F, et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer 2011; 18:429-37
42. Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCVrelated mixed cryoglobulinemia patients. Clin Exp Rheumatol 2002; 20:693-6
43. Latrofa F, Ricci D, Montanelli L, et al. Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin. J Clin Endocrinol Metab 2012; 97:2380-7
44. Boi F, Lai ML, Marziani B, et al. High prevalence of suspicious cytology in thyroid nodules associated with positive thyroid autoantibodies. Eur J Endocrinol 2005; 153:637-42
45. Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007; 17:447-51
46. Spinelli C, Bertocchini A, Antonelli A, et al. Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients < or =16 years old. J Pediatr Surg 2004; 39:1500-5
47. Neri S, Boraschi P, Antonelli A, et al. Pulmonary function, smoking habits, and high resolution computed tomography (HRCT) early abnormalities of lung and pleural fibrosis in shipyard workers exposed to asbestos. Am J Ind Med 1996; 30:588-95
48. Antonelli A, Miccoli P, Derzhitski VE, et al. Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus). World J Surg 1996; 20:867-71
49. Antonelli A, Fallahi P, Ferrari SM, et al. Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed Pharmacother 2008; 62:559-63
50. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTCRAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068-81
51. Puxeddu E, Knauf JA, Sartor MA, et al. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr Relat Cancer 2005; 12:319-34
52. Antonelli A, Ferrari SM, Fallahi P, et al. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferatoractivated receptor-gamma agonists. Endocr Relat Cancer 2009; 16:1299-311
53. Melillo RM, Guarino V, Avilla E, et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene 2010; 29:6203-15
54. Lytton SD, Kahaly GJ. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev 2010; 10:116-22
55. Tozzoli R, Bagnasco M, Giavarina D, et al. TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev 2012; 12:107-13
56. Mariotti S, Del Prete GF, Mastromauro C, et al. The autoimmune infiltrate of Basedow's disease: analysis of clonal level and comparison with Hashimoto's thyroiditis. Exp Clin Endocrinol 1991; 97:139-46
57. Garcià-Lòpez MA, Sancho D, Sànchez-Madrid F, et al. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 2001; 86:5008-16
58. Romagnani P, Rotondi M, Lazzeri E, et al. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recentonset Graves' disease. Am J Pathol 2002; 161:195-206
59. Antonelli A, Rotondi M, Ferrari SM, et al. Interferon-gammainducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferatoractivated receptor-gamma agonists. J Clin Endocrinol Metab 2006; 91:614-20
60. Antonelli A, Rotondi M, Fallahi P, et al. Increase of interferongamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) 2006; 64:189-95
61. Ashhab Y, Dominguez O, Sospedra M, et al. A one-tube polymerase chain reaction protocol demonstrates CC chemokine overexpression in Graves' disease glands. J Clin Endocrinol Metab 1999; 84:2873-82
62. Aust G, Sittig D, Becherer L, et al. The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases. Eur J Endocrinol 2004; 150:225-34
63. Armengol MP, Juan M, Lucas-Martin A, et al. Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol 2001; 159:861-73
64. Siddiqi A, Monson JP, Wood DF, et al. Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 1999; 84:435-9
65. Domberg J, Liu C, Papewalis C, et al. Circulating chemokines in patients with autoimmune thyroid diseases. Horm Metab Res 2008; 40:416-21
66. Inukai Y, Momobayashi A, Sugawara N, et al. Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease. Eur J Endocrinol 2007; 156:623-30
67. Crescioli C, Cosmi L, Borgogni E, et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol 2007; 195:145-55
68. Brück P, Bartsch W, Sadet D, et al. A CXC motif ligand 10 polymorphism as a marker to predict severity of Graves' disease. Thyroid 2010; 20:343-5
69. Sakai H, Togawa Y, Fukuda G, et al. Serum chemokine (C-X-C motif) ligand 10 levels are elevated in patients with Graves' disease in long-term remission. Thyroid 2010; 20:341-2
70. Antonelli A, Fallahi P, Rotondi M, et al. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006; 93:1226-31
71. Antonelli A, Rotondi M, Fallahi P, et al. Iodine-131 given for therapeutic purposes modulates differently interferongamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 2007; 92:1485-90
72. Leite AC, Pedro AB, Romaldini JH. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease. Horm Metab Res 2011; 43:194-9
73. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002; 12:855-60
74. Nielsen CH, El Fassi D, Hasselbalch HC, et al. B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family. Expert Opin Biol Ther 2007; 7:1061-78
75. Baschieri L, Antonelli A, Nardi S, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid 1997; 7:579-85
76. Piantanida E, Tanda ML, Lai A, et al. Prevalence and natural history of Graves' orbitopathy in the XXI century. J Endocrinol Invest 2013; 36:444-9
77. Dong QY, Li SJ, Gao GQ, et al. Short-term effect of radioactive iodine therapy on CXCL-10 production in Graves' disease. Clin Invest Med 2011; 34:E262
78. Mysliwiec J, Palyga I, Kosciuszko M, et al. Circulating CXCL9 and CXCL10 as Markers of Activity of Graves' Orbitopathy During Treatment with Corticosteroids and Teleradiotherapy. Horm Metab Res 2012; 44:957-61
79. Proudfoot AE, Power CA, Rommel C, et al. Strategies for chemokine antagonists as therapeutics. Semin Immunol 2003; 15:57-65
80. Marx N, Mach F, Sauty A, et al. Peroxisome proliferatoractivated receptor-gamma activators inhibit IFN-gammainduced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000; 164:6503-8
81. Gosset P, Charbonnier AS, Delerive P, et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol 2001; 31:2857-65
82. Schaefer KL, Denevich S, Ma C, et al. Intestinal antinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 2005; 11:244-52
83. Antonelli A, Ferrari SM, Fallahi P, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009; 94:1803-9
84. Antonelli A, Ferrari SM, Fallahi P, et al. Cytokines (interferon-? and tumor necrosis factor-a)-induced nuclear factor-?B activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism 2011; 60:277-83
85. Spencer NF, Poynter ME, Im SY, et al. Constitutive activation of NF-kappa B in an animal model of aging. Int Immunol 1997; 9:1581-8
86. Oliveira AC, Bertollo CM, Rocha LT, et al. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol 2007; 561:194-201
87. Lee JW, Bajwa PJ, Carson MJ, et al. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10 deficient mice. Gastroenterol 2007; 133:108-23
88. Antonelli A, Ferrari SM, Frascerra S, et al. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferatoractivated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab 2010; 95:E413-20
89. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274:32048-54
90. Pascual G, Fong AL, Ogawa S, et al. A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437:759-63